시장보고서
상품코드
1726127

단백질체학 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 기술별, 용도별, 지역별, 부문 예측(2025-2030년)

Proteomics Market Size, Share & Trends Analysis Report By Product & Service (Services, Reagents & Consumables, Instruments), By Technology (Spectrometry, Microarray), By Application, By Region, And Segment Forecasts, 2025 - 2030

발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

단백질체학 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계 단백질체학 시장 규모는 2030년에 581억 6,000만 달러에 달할 것으로 예측되며, 2025-2030년에 걸쳐 12.9%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예측되고 있습니다.

이 산업의 성장을 견인하는 주요 요인은 맞춤형 의료에 대한 수요가 높아지고, 단백질체학 질량 분석계나 바이오칩 플랫폼을 활용한 진단의 파이프라인의 확대, 유전체학에 의한 발견입니다. 제약회사가 독자적인 단백질체학 부문을 설립하고 있으며, 이것이 세계 산업의 확대에 박차를 가하고 있습니다.

세계 연구자들이 SARS-CoV-2 단백질의 3D 구조 해독에 집중하고 있기 때문에 COVID-19의 발생은 산업에 큰 영향을 미칠 것으로 예측됩니다. 규범에서 효율적인 표적 치료를 찾기 위해서는 바이러스 단백질의 구조와 그 특정 위치를 이해할 필요가 있습니다.

게다가 질량분석 기반 단백질체학의 개량과 바이오마커 동정과 관련된 유리한 기회로 단백질체학의 매력적인 시장 확대 가능성이 예상됩니다. Bruker Corp.는 2017년 9월 PASEF(Parallel Accumulation And Serial Fragmentation) 질량분석을 위한 timsTOF Pro 시스템을 발표했습니다. Spectrometry(TIMS) 기술을 사용하고 있으며, 또한 단백질체학 연구의 진보로 단백질 바이오마커의 검출, 단백질 바이오칩 & 파마코단백질체학, 단백질체학에 의한 분자진단이 가속되고 있으며, 이들 모두 맞춤형 의료의 발전에 크게 공헌하고 있습니다.

단백질체학 시장 보고서 하이라이트

  • 심혈관 질환, 당뇨병, 암 등의 만성 질환은 세계의 이환율과 사망률의 상당 부분을 차지하고 있습니다.
  • 단백질체학 산업은 질량 분석과 차세대 시퀀싱 기술의 기술적 진보에 견인되어 큰 기술 혁신을 경험하고 있습니다.
  • 시약 및 소모품 부문은 2024년에 72.53%의 최대 수익 점유율을 차지했습니다.
  • 스펙트로메트리 부문은 2024년에 31.88%의 최대 수익 점유율을 획득했습니다.
  • 신약 부문은 2024년에 52.73%의 최대 수익 점유율을 얻었으며, 단백질체학 시장을 독점했습니다.
  • 북미 단백질체학 시장은 세계 시장을 독점해, 2024년의 매출액 점유율은 45.75%였습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 단백질체학 시장의 변수, 동향, 범위

  • 시장 계통의 전망
    • 모 시장 전망
    • 관련/보조적인 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 단백질체학 시장 분석 툴
    • 산업 분석 - Porter's Five Forces 분석
    • PESTEL 분석
    • COVID-19의 영향 분석

제4장 단백질체학 시장 : 제품 및 서비스별, 추정 및 동향 분석

  • 부문 대시보드
  • 세계의 단백질체학 시장의 제품 및 서비스 변동 분석
  • 세계의 단백질체학 시장 규모와 동향 분석(제품 및 서비스별, 2018-2030년)
  • 기기
  • 시약 및 소모품
  • 서비스

제5장 단백질체학 시장 : 용도별, 추정 및 동향 분석

  • 부문 대시보드
  • 세계의 단백질체학 시장의 용도 변동 분석
  • 세계의 단백질체학 시장 규모와 동향 분석(용도별, 2018-2030년)
  • 신약
  • 임상 진단
  • 기타

제6장 단백질체학 시장 : 기술별, 추정 및 동향 분석

  • 부문 대시보드
  • 세계의 단백질체학 시장의 기술 변동 분석
  • 세계의 단백질체학 시장 규모와 동향 분석(기술별, 2018-2030년)
  • 차세대 시퀀싱
  • 마이크로어레이 기기
  • X선 결정 구조 분석
  • 분광분석
  • 크로마토그래피
  • 단백질 분획 시스템
  • 전기영동
  • 표면 플라즈마 공명(SPR) 시스템
  • 기타

제7장 단백질체학 시장 : 지역별, 추정 및 동향 분석

  • 지역별 시장 점유율 분석, 2024년, 2030년
  • 지역별 시장 대시보드
  • 시장 규모, 예측 동향 분석, 2018-2030년
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 노르웨이
    • 스웨덴
    • 덴마크
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제8장 경쟁 구도

  • 기업/경쟁의 분류
  • 전략 매핑
  • 기업시장 포지셔닝 분석, 2024년
  • 기업 프로파일/상장 기업
    • Illumina Inc.
    • Agilent Technologies Inc.
    • Bio-Rad Laboratories, Inc.
    • Thermo Fisher Scientific, Inc.
    • Bruker Corporation
    • F. Hoffmann-La Roche Ltd.
    • Waters Corporation
    • Merck KGaA
    • Danaher
    • Standard BioTools Inc.
SHW 25.05.27

Proteomics Market Growth & Trends:

The global proteomics market size is expected to reach USD 58.16 billion in 2030 and is projected to grow at a CAGR of 12.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The major factors driving theindustry growth are a rise in the demand for personalized medicine, an expansion of the pipeline of diagnostics utilizing proteomics mass spectrometry as well as biochip platforms, and discoveries based on genomics. Moreover, owing to the importance of proteomics in drug development, numerous pharmaceutical companies have established their own proteomic divisions, which are fueling the expansion of the global industry. For instance, in September 2021, Biognosys, announced the collaboration with Evotec, to promote the use of next-generation proteomics in clinical research and drug discovery.

The COVID-19 outbreak is expected to have a significant impact on the industry, as researchers across the world are concentrating on decoding 3D structures of SARS-CoV-2 proteins. To create effective medications and biological products against COVID-19, scientists are also attempting to examine the identification techniques, structures, characterization, and interactions of these proteins. The protein structure of virus proteins and their specific locations must be understood to find a novel, efficient target treatment medication for a virus. Therefore, it will increase the demand for drug development for COVID-19 and propel industry growth. The growing need for customized medications increased R&D spending, and technological developments related to proteomics components are also driving the market.

In addition, attractive market expansion potential for proteomics is anticipated to come from improvements in mass spectrometry-based proteomics and lucrative opportunities related to biomarker identification. Thereby, propelling the market growth.The introduction of new and improved proteomics techniques by major industry participants is projected to further accelerate the growth of the industry. For instance, to provide quick data acquisition for shotgun proteomics, Bruker Corp. introduced the timsTOF Pro system for Parallel Accumulation And Serial Fragmentation (PASEF) mass spectrometry in September 2017. This system uses proprietary Trapped Ion Mobility Spectrometry (TIMS) technology.Furthermore, proteomic research advancements have accelerated the detection of protein biomarkers, protein biochips & pharmacoproteomics, and proteomics-based molecular diagnostics, which have all made significant contributions to the development of personalized medicine.

Proteomics Market Report Highlights:

  • Chronic diseases, such as cardiovascular conditions, diabetes, and cancer, account for a substantial portion of global morbidity and mortality.
  • The proteomics industry is experiencing a significant degree of innovation driven by technological advancements in mass spectrometry and next-generation sequencing technology.
  • The reagents & consumables segment accounted for the largest revenue share of 72.53% in 2024. Kits designed for mass spectrometry enable researchers to identify proteins within complex biological samples accurately
  • The spectrometry segment captured the largest revenue share of 31.88% in 2024. It is also expected to expand further at the highest during the forecast period
  • The drug discovery segment dominated the proteomics market with the largest revenue share of 52.73% in 2024. This large share can be attributed to the development of structure-based drug design, a greater emphasis on creating personalized drugs, and increased investments in these areas.
  • North America Proteomics market dominated the global market and accounted for 45.75% revenue share in 2024, owing to the advancements in technology and growing demand for advanced disease diagnostics

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Product & Service Segment
    • 1.2.2. Application Segment
    • 1.2.3. Technology Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Proteomics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of chronic and infectious diseases
      • 3.2.1.2. Growing preference for personalized medicine
      • 3.2.1.3. Technological advancements in proteomics techniques
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of proteomics tools and instruments
  • 3.3. Proteomics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Proteomics Market: Product & Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Proteomics Market Product & Service Movement Analysis
  • 4.3. Global Proteomics Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
  • 4.4. Instruments
    • 4.4.1. Instruments market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Reagents & Consumables
    • 4.5.1. Reagents & consumables market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Services
    • 4.6.1. Services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Proteomics Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Proteomics Market Application Movement Analysis
  • 5.3. Global Proteomics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Drug Discovery
    • 5.4.1. Drug discovery market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Clinical Diagnostics
    • 5.5.1. Clinical diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Proteomics Market: Technology Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Proteomics Market Technology Movement Analysis
  • 6.3. Global Proteomics Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
  • 6.4. Next-generation Sequencing
    • 6.4.1. Next-generation sequencing market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Microarray Instruments
    • 6.5.1. Microarray instruments market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. X-ray Crystallography
    • 6.6.1. X-ray crystallography market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Spectrometry
    • 6.7.1. Spectrometry market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Chromatography
    • 6.8.1. Chromatography market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Protein Fractionation Systems
    • 6.9.1. Protein fractionation systems market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10. Electrophoresis
    • 6.10.1. Electrophoresis market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.11. Surface Plasma Resonance (SPR) Systems
    • 6.11.1. Surface plasma resonance (SPR) systems market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.12. Other Technologies
    • 6.12.1. Other technologies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Proteomics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Competitive scenario
      • 7.5.8.3. Regulatory framework
      • 7.5.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.9. Denmark
      • 7.5.9.1. Key country dynamics
      • 7.5.9.2. Competitive scenario
      • 7.5.9.3. Regulatory framework
      • 7.5.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Competitive scenario
      • 7.6.7.3. Regulatory framework
      • 7.6.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Competitive scenario
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Competitive scenario
      • 7.8.4.3. Regulatory framework
      • 7.8.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key country dynamics
      • 7.8.5.2. Competitive scenario
      • 7.8.5.3. Regulatory framework
      • 7.8.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024
  • 8.4. Company Profiles/Listing
    • 8.4.1. Illumina Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product/Service benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Agilent Technologies Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product/Service benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Bio-Rad Laboratories, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product/Service benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Thermo Fisher Scientific, Inc.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product/Service benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Bruker Corporation
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product/Service benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. F. Hoffmann-La Roche Ltd.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product/Service benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Waters Corporation
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product/Service benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Merck KGaA
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product/Service benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Danaher
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product/Service benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Standard BioTools Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product/Service benchmarking
      • 8.4.10.4. Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제